MX2018002157A - Conjugados de aldehido y usos de los mismos. - Google Patents

Conjugados de aldehido y usos de los mismos.

Info

Publication number
MX2018002157A
MX2018002157A MX2018002157A MX2018002157A MX2018002157A MX 2018002157 A MX2018002157 A MX 2018002157A MX 2018002157 A MX2018002157 A MX 2018002157A MX 2018002157 A MX2018002157 A MX 2018002157A MX 2018002157 A MX2018002157 A MX 2018002157A
Authority
MX
Mexico
Prior art keywords
aldehyde
hne
mda
pathogenesis
implicated
Prior art date
Application number
MX2018002157A
Other languages
English (en)
Inventor
A Kinney William
brady Todd
Young Scott
Original Assignee
Aldeyra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldeyra Therapeutics Inc filed Critical Aldeyra Therapeutics Inc
Publication of MX2018002157A publication Critical patent/MX2018002157A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/16—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with only hydrogen or carbon atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención proporciona compuestos y métodos de uso de los mismos para tratar, prevenir y/o reducir el riesgo de enfermedad, trastorno o condición en el cual la toxicidad por aldehído está implicada en la patogénesis incluyendo trastornos oculares, dérmicos, condiciones asociadas a los efectos dañinos de agentes ampollantes, y enfermedades autoinmunes, inflamatorias, neurológicas y cardiovasculares mediante el uso de una amina primaria para secuestrar aldehídos tóxicos, como MDA y HNE.
MX2018002157A 2015-08-21 2016-08-22 Conjugados de aldehido y usos de los mismos. MX2018002157A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562208278P 2015-08-21 2015-08-21
US201662315455P 2016-03-30 2016-03-30
US201662347464P 2016-06-08 2016-06-08
PCT/US2016/048064 WO2017035082A1 (en) 2015-08-21 2016-08-22 Aldehyde conjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX2018002157A true MX2018002157A (es) 2018-06-08

Family

ID=58100899

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002157A MX2018002157A (es) 2015-08-21 2016-08-22 Conjugados de aldehido y usos de los mismos.

Country Status (14)

Country Link
US (3) US20180250306A1 (es)
EP (1) EP3337470A4 (es)
JP (2) JP6959650B2 (es)
KR (1) KR20180073553A (es)
CN (2) CN108135867A (es)
AU (1) AU2016311163A1 (es)
BR (1) BR112018003264A2 (es)
CA (1) CA2996186A1 (es)
CL (1) CL2018000462A1 (es)
CO (1) CO2018002841A2 (es)
HK (1) HK1256143A1 (es)
IL (1) IL257615A (es)
MX (1) MX2018002157A (es)
WO (1) WO2017035082A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336117A1 (en) 2005-05-26 2011-06-22 Neuron Systems, Inc Heterocyclic compounds for treating retinal diseases
CA3195807A1 (en) 2013-01-23 2014-07-31 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
CA2996183A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CA3016759A1 (en) 2016-02-28 2017-08-31 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
WO2018039192A1 (en) * 2016-08-22 2018-03-01 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and uses thereof
JP2020511461A (ja) * 2017-03-16 2020-04-16 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
AU2018348174A1 (en) * 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
CN115869258A (zh) 2018-09-25 2023-03-31 奥尔德拉医疗公司 用于治疗干眼病的调配物
US20220133697A1 (en) * 2018-12-05 2022-05-05 Aldeyra Therapeutics, Inc. Injectable formulations
MX2021007140A (es) * 2018-12-18 2021-11-03 Medshine Discovery Inc Compuesto para usarse en enfermedades de la retina.
WO2020198064A1 (en) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
BR112022012641A2 (pt) * 2019-12-27 2022-09-06 Lupin Ltd Compostos tricíclicos substituídos
US20230021669A1 (en) * 2019-12-30 2023-01-26 The National Institutes of Pharmaceutical R&D Co., Ltd. Tricyclic compound, and preparation method therefor and medical use thereof
CN115551507A (zh) * 2020-04-13 2022-12-30 奥尔德拉医疗公司 用于治疗肺、肝脏和肾脏疾病、病症或病况的喹啉化合物
CN115916753A (zh) * 2020-06-17 2023-04-04 南京明德新药研发有限公司 2-甲基2-丙醇和氨基取代的芳基化合物的晶型
US20230174524A1 (en) * 2020-06-17 2023-06-08 Medshine Discovery Inc. Aminopyridine compound
CA3194065A1 (en) * 2020-09-28 2022-03-31 Peng Li Crystal form of pyridinylphenyl compound and preparation method therefor
AU2021413207A1 (en) * 2020-12-29 2023-06-29 The National Institutes Of Pharmaceutical R&D Co., Ltd Tricyclic compound, and preparation method therefor and medical use thereof
CN115843293A (zh) * 2021-06-25 2023-03-24 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
WO2024109905A1 (zh) * 2022-11-26 2024-05-30 珠海联邦制药股份有限公司 一种含有吡啶苯基类化合物的眼用制剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358948B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
EP2336117A1 (en) * 2005-05-26 2011-06-22 Neuron Systems, Inc Heterocyclic compounds for treating retinal diseases
JP5793459B2 (ja) * 2012-03-30 2015-10-14 新日鐵住金ステンレス株式会社 加工性に優れた耐熱フェライト系ステンレス冷延鋼板、冷延素材用フェライト系ステンレス熱延鋼板及びそれらの製造方法
EP2935220A4 (en) * 2012-12-20 2016-04-27 Aldeyra Therapeutics Inc PERI-carbinol
CA3195807A1 (en) * 2013-01-23 2014-07-31 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment

Also Published As

Publication number Publication date
CN114085236A (zh) 2022-02-25
JP2018530524A (ja) 2018-10-18
IL257615A (en) 2018-04-30
EP3337470A4 (en) 2019-02-27
WO2017035082A1 (en) 2017-03-02
US20200246345A1 (en) 2020-08-06
CO2018002841A2 (es) 2018-07-10
CL2018000462A1 (es) 2018-08-17
HK1256143A1 (zh) 2019-09-13
AU2016311163A1 (en) 2018-04-05
CN108135867A (zh) 2018-06-08
BR112018003264A2 (pt) 2018-09-25
JP7332186B2 (ja) 2023-08-23
US20220354857A1 (en) 2022-11-10
JP6959650B2 (ja) 2021-11-02
KR20180073553A (ko) 2018-07-02
JP2022000469A (ja) 2022-01-04
EP3337470A1 (en) 2018-06-27
US20180250306A1 (en) 2018-09-06
CA2996186A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
MX2018002157A (es) Conjugados de aldehido y usos de los mismos.
MX2019001722A (es) Compuestos de captura de aldehido y usos de los mismos.
MX2018002155A (es) Compuestos deuterados y usos de los mismos.
MX2019012878A (es) Terapias para el tratamiento de enfermedades asociadas con la toxicidad del aldehido.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12019500204A1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
EA201691514A1 (ru) Соединения
MX2016011038A (es) Compuestos para el tratamiento de trastornos mediados por complemento.
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
NZ720949A (en) Methods and compositions for treating aging-associated conditions
EA201990400A1 (ru) Соединения и композиции и их применение
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
EA202090414A1 (ru) Соединения и их применение
EA201792610A1 (ru) Способ лечения неврологического заболевания
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
PH12019500198A1 (en) Compounds and compositions and uses thereof
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
PH12017500114A1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
EA202191115A1 (ru) Новые пиридазины
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease
MX2016008968A (es) Compuestos organicos.